Not Yet Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923
- Conditions
- Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +20 more
- Locations
-
- Hackensack University Medical Center Hackensack, New Jersey, United States
- NYU Langone Health New York, United States
- Sarah Cannon Research Institute (SCRI) Nashville, Tennessee, United States
- UT Southwestern Medical Center Dallas, Texas, United States